20 Participants Needed

Artificial Disc Implants for Cervical Spondylosis

MT
DC
SH
Overseen BySandra Holley, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Los Angeles
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines two types of artificial disc implants to treat neck pain from conditions like cervical spondylotic myelopathy or radiculopathy, often due to disc problems. The researchers aim to assess how well the Biomet Zimmer Mobi-C and Nuvasive Simplify implants improve neck movement, reduce pain, and enhance quality of life. Participants will be randomly assigned one of the implants, with their recovery and outcomes monitored for about a year and a half. This trial suits individuals with persistent neck issues from cervical disc problems who have not improved with other treatments. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the chance to contribute to the validation of a potentially groundbreaking treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that these artificial disc implants are safe for treating cervical spondylotic myelopathy and/or radiculopathy?

Research has shown that both the Biomet Zimmer Mobi-C and Nuvasive Simplify artificial disc implants are safe for cervical disc replacement. Studies have found that the Mobi-C implant performs well over the long term, with more than 82% of patients experiencing less pain and improved neck movement without major issues.

Similarly, the Nuvasive Simplify disc has demonstrated a high success rate two years post-surgery. Patients with this implant have reported positive outcomes, and it is considered safe compared to standard surgical options.

Both implants have FDA approval, indicating they meet safety standards for their intended use. While any surgery carries risks, such as reactions to anesthesia, both implants have a history of being well-tolerated by patients.12345

Why are researchers excited about this trial?

Researchers are excited about the investigational cervical disc implants because they offer different mechanical designs that could improve outcomes for patients with cervical disc issues. The Nuvasive Simplify disc features a semi-constrained design with a mobile core that allows for more natural motion, potentially reducing stress on adjacent spinal segments. In contrast, the Biomet Zimmer Mobi-C implant is unconstrained, which might provide even greater flexibility and movement, further mimicking the spine's natural biomechanics. These innovative designs could lead to better preservation of neck movement and less wear and tear on the spine compared to traditional spinal fusion surgeries.

What evidence suggests that these artificial disc implants are effective for cervical spondylotic myelopathy and/or radiculopathy?

This trial will compare the Nuvasive Simplify and Biomet Zimmer Mobi-C artificial disc implants for neck spine issues. Research has shown that the Nuvasive Simplify Disc, used in one arm of this trial, achieves a much higher success rate two years post-surgery compared to traditional methods. Patients report that this implant is safer and more effective. In contrast, the Biomet Zimmer Mobi-C, used in another arm of this trial, has demonstrated long-term results that maintain neck movement and reduce pain more effectively than standard surgery. Many patients express high satisfaction with their outcomes. Both implants offer effective solutions for neck conditions like cervical spondylotic myelopathy and radiculopathy.12346

Who Is on the Research Team?

DC

Daniel C Lu, MD, PhD

Principal Investigator

University of California, Los Angeles

Are You a Good Fit for This Trial?

Inclusion Criteria

Experiences cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7
Is unresponsive to at least six weeks of non-surgical conservative care
Has the intention of undergoing cervical arthroplasty for their chief complaint
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Baseline testing conducted to evaluate neck disability, quality of life, pain, physiological outcome, and neck range-of-motion

1 day
1 visit (in-person)

Surgery and Initial Recovery

Participants undergo cervical arthroplasty with either the Nuvasive Simplify or Biomet Zimmer Mobi-C artificial disc implant

1-2 weeks
1 visit (in-person)

Post-operative Follow-up

Participants are monitored for safety and effectiveness with assessments at 3 months, 6 months, and 1 year post-operation

1 year
3 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Biomet Zimmer Mobi-C
  • Nuvasive Simplify

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Unconstrained Biomet Zimmer Mobi-CExperimental Treatment2 Interventions
Group II: Semi-Constrained Nuvasive SimplifyExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials
1,594
Recruited
10,430,000+

Citations

Long-term Evaluation of Cervical Disc Arthroplasty with ... - PMC

In the single level cohort, there was an increased percentage of TDR patients who reported themselves as “very satisfied” (TDR 90.9% vs ACDF 77.8%; p= 0.028).

and 2-Level Cervical Disc Arthroplasty From the Mobi-C ...

CONCLUSION: Our results through 10 yr were comparable to 7-yr outcomes, demon- strating that CDA with Mobi-C continues to be a safe and effective surgical ...

Zimmer Biomet Spine Announces Mobi-C® Cervical Disc ...

Researchers found that cTDR with Mobi-C was associated with lower pain scores, maintained range of motion, less adjacent level degeneration and ...

Two-level total disc replacement with Mobi-C cervical artificial ...

The overall success of TDR, a composite outcome consisting of 5 components, was statistically superior (p < 0.0001) to ACDF at 48 months with ...

Cervical Arthroplasty: Long-Term Outcomes of FDA IDE Trials

Overall success rates, as defined in the study as primary effectiveness and safety measures, were achieved in 82.6% of artificial disc patients and only 72.7% ...

Comparison of Artificial Disc Implants in Cervical ...

This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to ...